InflaRx N.V. Gets EU Approval for GOHIBIC® for ARDS
Ticker: IFRX · Form: 6-K · Filed: Jan 15, 2025 · CIK: 1708688
Sentiment: bullish
Topics: regulatory-approval, pharmaceutical, covid-19, europe
TL;DR
EU approves InflaRx's GOHIBIC® for COVID-19 ARDS on Jan 15, 2025!
AI Summary
On January 15, 2025, InflaRx N.V. announced that the European Commission has granted marketing authorization under exceptional circumstances for GOHIBIC® (vilobelimab). This approval is for the treatment of adult patients suffering from SARS-CoV-2-induced acute respiratory distress syndrome (ARDS).
Why It Matters
This European Commission approval provides a new treatment option for critically ill COVID-19 patients with ARDS, potentially improving outcomes for a severe condition.
Risk Assessment
Risk Level: medium — While a significant approval, the 'exceptional circumstances' designation and focus on a specific severe condition suggest potential limitations or ongoing evaluation.
Key Players & Entities
- InflaRx N.V. (company) — Filer of the report and recipient of the approval
- GOHIBIC® (drug) — The drug that received marketing authorization
- vilobelimab (drug) — The active ingredient in GOHIBIC®
- European Commission (company) — Regulatory body granting the approval
- January 15, 2025 (date) — Date of the press release and approval
FAQ
What is the specific indication for GOHIBIC® in the European Union?
GOHIBIC® (vilobelimab) is approved for the treatment of adult patients with SARS-CoV-2-induced acute respiratory distress syndrome (ARDS).
Under what conditions was GOHIBIC® approved by the European Commission?
The marketing authorization was granted under exceptional circumstances.
What is the trade name of the drug approved?
The trade name of the approved drug is GOHIBIC®.
What is the active ingredient in GOHIBIC®?
The active ingredient is vilobelimab.
When was this approval announced by InflaRx N.V.?
The announcement was made on January 15, 2025.
Filing Stats: 576 words · 2 min read · ~2 pages · Grade level 13 · Accepted 2025-01-15 16:33:37
Filing Documents
- ef20041675_6k.htm (6-K) — 12KB
- ef20041675_ex99-1.htm (EX-99.1) — 17KB
- image00001.jpg (GRAPHIC) — 3KB
- 0001140361-25-001187.txt ( ) — 35KB
FORWARD-LOOKING STATEMENTS
FORWARD-LOOKING STATEMENTS This Report contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential" or "continue," among others. Forward-looking statements appear in a number of places throughout this Report and may include statements regarding our intentions, beliefs, projections, outlook, analyses, current expectations and the risks, uncertainties and other factors described under the heading "Risk Factors" and "Cautionary statement regarding forward looking results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law. EXHIBIT INDEX Exhibit No. Description 99.1 Press Release, dated January 15, 2025
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INFLARX N.V. Date: January 15, 2025 By: /s/ Niels Riedemann Name: Niels Riedemann Title: Chief Executive Officer